Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

61.25 -0.58 (-0.94%)
Streaming Delayed Price Updated: 9:58 AM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
NASDAQ:BMRN is not too expensive for the growth it is showing. ↗
While growth is established for BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), the stock's valuation remains reasonable. 
Via Chartmill
News headline image
$1000 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance ↗
BioMarin Pharmaceutical shifts focus to commercial operations for Roctavian in the U.S., Germany, and Italy. Projected cost reductions aim to achieve profitability by 2025. Strong Q2 performance driven... 
Via Benzinga
News headline image
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN. ↗
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock which is not overvalued. 
Via Chartmill
News headline image
$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today ↗
 
Via Benzinga
News headline image
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results ↗
 
Via Benzinga
News headline image
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Beats Revenue for Q2 2024 ↗
BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts ↗
 
Via Benzinga
News headline image
$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Peering Into Biomarin Pharmaceutical's Recent Short Interest ↗
 
Via Benzinga
News headline image
Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced. ↗
Investors should take note ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock that remains attractively priced. 
Via Chartmill
News headline image
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical ↗
 
Via Benzinga
News headline image
Looking Into Biomarin Pharmaceutical's Recent Short Interest ↗
 
Via Benzinga
News headline image
NASDAQ:BMRN is not too expensive for the growth it is showing. ↗
Looking for growth without the hefty price tag? Consider BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN). 
Via Chartmill
News headline image
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. ↗
While growth is established for BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), the stock's valuation remains reasonable. 
Via Chartmill
News headline image
CrowdStrike, KKR, GoDaddy To Join S&P 500 In Quarterly Rebalance; Stocks Jump ↗
KKR and GoDaddy also will join before the open on June 24. 
Via Investor's Business Daily
Topics Stocks
News headline image
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Analyst Ratings For Biomarin Pharmaceutical ↗
 
Via Benzinga
News headline image
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest ↗
 
Via Benzinga
News headline image
BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results ↗
BridgeBio stock rallies on upbeat study results of a drug for a genetic disease that affects the limbs and spine. 
Via Investor's Business Daily
News headline image
Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024) ↗
Last week, these 10 large-cap stocks had the worst performance. NICE, PBR, FIX, LI, MLM, VMC, BMRN, EDU, GFI, MUFG all saw significant decreases. 
Via Benzinga
News headline image
4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market ↗
Plain-as-day bargains can still be found, even with the innovation-fueled Nasdaq Composite powering to a fresh all-time high. 
Via The Motley Fool
Topics Stocks
News headline image
Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
The 3 Best Biotech Stocks to Buy in May 2024 ↗
If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May. 
Via InvestorPlace
News headline image
Citi Just Cut Its Price Target on These 3 Stocks ↗
Reviewing analyst downgrades may help safeguard investment portfolios amid market uncertainty and Citi price target cuts. 
Via InvestorPlace
News headline image
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. ↗
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.